Forsta AP Fonden Decreases Position in Catalent, Inc. (NYSE:CTLT)

Forsta AP Fonden reduced its position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 52.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,900 shares of the company's stock after selling 19,800 shares during the quarter. Forsta AP Fonden's holdings in Catalent were worth $1,007,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in shares of Catalent by 29.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company's stock valued at $73,655,000 after purchasing an additional 376,931 shares during the last quarter. UBS Group AG increased its holdings in shares of Catalent by 2.6% during the fourth quarter. UBS Group AG now owns 726,563 shares of the company's stock worth $32,644,000 after buying an additional 18,752 shares in the last quarter. Gamco Investors INC. ET AL boosted its stake in Catalent by 403.3% in the first quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company's stock worth $1,428,000 after purchasing an additional 20,273 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Catalent by 2,792.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company's stock worth $29,150,000 after acquiring an additional 498,540 shares during the last quarter. Finally, UniSuper Management Pty Ltd increased its holdings in shares of Catalent by 509.4% in the first quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company's stock valued at $1,028,000 after purchasing an additional 15,217 shares in the last quarter.

Catalent Stock Up 0.4 %

Shares of CTLT traded up $0.23 during trading hours on Tuesday, hitting $60.39. The stock had a trading volume of 2,170,127 shares, compared to its average volume of 2,103,513. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.77. The firm has a 50 day simple moving average of $59.33 and a 200-day simple moving average of $57.15. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20. The firm has a market capitalization of $10.93 billion, a P/E ratio of -9.90, a price-to-earnings-growth ratio of 1.88 and a beta of 1.15.

Insider Transactions at Catalent

In other news, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, SVP Scott Gunther sold 666 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the sale, the senior vice president now owns 39,635 shares of the company's stock, valued at $2,360,264.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Alessandro Maselli sold 9,088 shares of the firm's stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now directly owns 177,521 shares of the company's stock, valued at $10,431,133.96. The disclosure for this sale can be found here. Insiders sold a total of 13,409 shares of company stock worth $782,923 in the last quarter. 0.31% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CTLT. StockNews.com initiated coverage on Catalent in a report on Tuesday, September 10th. They issued a "sell" rating for the company. William Blair reaffirmed a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Barclays increased their price target on Catalent from $47.00 to $63.00 and gave the company an "equal weight" rating in a research report on Friday, June 28th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $58.08.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.